<DOC>
	<DOCNO>NCT02411253</DOCNO>
	<brief_summary>Type 1diabetes ( T1D ) cause autoimmune destruction pancreatic islet ß-cells , lead absolute deficiency insulin . In health , regulatory T cell ( Tregs ) suppress immune response normal tissue , likewise prevent autoimmune disease . Tregs insufficient T1D . The investigator previously show administration low dose IL-2 induces selective expansion activation Tregs mouse human . The investigator hypothesize Tregs expansion activation low dos IL2 could block ongoing autoimmune destruction insulin produce cell patient recently diagnose T1D .</brief_summary>
	<brief_title>Low-dose rhIL-2 Patients With Recently-diagnosed Type 1 Diabetes</brief_title>
	<detailed_description>Scientific justification : Clinical preclinical study , together supportive mechanistic data show Tregs activate much low IL-2 concentration effector T cell ( Teffs ) , provide strong rationale study efficacy low dose IL2 stop autoimmune destruction insulin-secreting beta cell patient recently diagnose T1D . Primary objective : 1 . To evaluate efficacy low dose IL-2 preservation residual pancreatic β cell function 2 . To select optimal regimen administration IL-2 Primary assessment criterion : AUC ( T0-T120 ) serum C-peptide , determine mixed meal tolerance test month 12 , compare baseline . Secondary objective : 1 . To assess Tregs expansion induction period maintenance therapy 2 . To assess safety IL-2 treatment period ( 1 year ) 1 year discontinuation 3 . To assess relation Tregs expansion preservation residual pancreatic β cell function 4 . To assess clinical biological response accord ( ) pubertal stage group , ( ) time diagnosis treatment initiation , ( iii ) biomarkers responses 5 . To assess effect IL-2 disease-specific immune response 6 . To identify biomarkers predicting/monitoring safety efficacy IL-2 . Secondary assessment criterion : - Serum concentration C-peptide - AUC ( T0-T120 ) serum C-peptide mixed meal tolerance test treatment discontinuation - Diabetic monitoring ( insulin use ) - HbA1c IDAA1c score - Number hypoglycaemic episode ( &lt; 0.5 g/L capillary sample ) 15 day visit . - Number clinically significant symptomatic episode hypoglycaemia visit . - Change Tregs ( express percentage CD4 absolute number ) day 5 compare baseline . - Change trough level Tregs ( % CD4+ absolute number ) month 1 , month 3 , month 6 , month 9 , month 12 , compare baseline ; month 15 24 treatment discontinuation . - Change Foxp3 gene methylation - Cytokines chemokines assay day 5 , month 1 , month 3 , month 6 , month 9 , month 12 compare baseline month 15 month 24 treatment discontinuation . - Transcriptome analysis . - Genotyping baseline - Treg phenotype functionality adult adolescent include pStat5 analysis Pharmacokinetic IL2 perform ( patient regimen A ) day 1 T0 , T60min ( 1h ) , T120min ( 2h ) , T240min ( 4h ) , T360min ( 6h ) , T600min ( 10h ) , T1440min ( 24h=day2 ) day 4 , V8 ( D29±1day ) V54 ( day 351±3 day ) time point 27 patient regimen A . • Safety parameter evaluate clinical examination ( include height/weight pubertal stage especially child adolescent ) , routine laboratory test , ILT-101 auto-antibodies , ancillary investigation adverse event . Experimental design : This multicenter European , sequential-group , randomize , double-blind trial evaluate IL-2 versus placebo Population involve : Male female , age 12 35 year , type 1 diabetes diagnose less two month . Number subject : 138 Inclusion period : 12 month Duration patient participation : 24 month ( treatment period : 12 month , follow-up period : 12months ) Total duration study : 36 month Statistical analysis : The principal efficacy analysis draw intention treat group . The per-protocol analysis use confirm intention treat analysis . For regimen : - MMTT : C-peptide concentration summarize AUC T0 T+120 min . Before statistical analysis , log ( x+1 ) normalize transformation use , IL-2 placebo treat patient compare use mixed model ANCOVA include baseline value covariate factor pubertal stage group . Quantitative endpoint analyze use method primary endpoint . Categorical endpoint analyze use multivariate logistic regression model . Subgroups analyse : Response treatment analyse accord criterion : - Pubertal stage , age , gender , BMI… - Biomarkers ( identify previous study predictive patient ' response treatment ) Funding source : European Commission Health Cooperation Programme Seventh Framework Programme ( Grant Agreement n°305380-2 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion criterion Age 1235 year old . Male female use effective method contraception treatment sexually active . Specifically ; Females ( sexually active ) childbearing potential must use contraceptive method consider highlyeffective ( pearl index &lt; 1 ) . The following method acceptable : Oral , injectable , implanted hormonal contraceptive ( exception oral minipills ie lowdose gestagens acceptable ( lynestrenol norestisteron ) , Intrauterine device , Intrauterine system ( example , progestinreleasing toit ) , beta HCG negative inclusion ; With type1 diabetes : Newly diagnose ( ADA criterion , see annexe 19.6 ) two month insulin initiation anticipate start experimental treatment . Positive one autoantibodies typically associate T1D ( antiislet , insulin , GAD , IA2 , ZnT8 ) With detectable peak Cpeptide concentration standardise MMTT Visit MMTT ( ≥0.2pmol/ml ) ; patient stable blood glucose level seric glycaemia 60 mg/dL 250 mg/dL verify MMTT visit Absence clinically significant abnormal laboratory value ( range associate clinical symptom sign ) haematology , biochemistry , thyroid , liver kidney function ; Normal cardiac function : documented history heart disease absence family history sudden death , normal ECG especially QTc duration within normal value ( &lt; 480ms ) ; Free , inform write consent , sign patient investigator Study examination . If patient minor child parent child legal representative case one parent alive . ( Journal officiel des communautés européennes ( 1.5.2001 ) NB : patient history thyroidism treatment inclusion normal thyroid hormone value ( TSH+T4 ) include . Exclusion criterion Children age 12 year old include Patient , inclusion , treat antidiabetic medication Insulin 3 month consecutively Chronic adrenal insufficiency know fast ACTH ≥2.5 ULN normal inclusion control ; Anti TPO present inclusion abnormal TSH T4 Antitransglutaminase positive inclusion Hypersensitivity active substance excipients Any major health problem include : major autoimmune/autoinflammatory disease ( type 1 diabetes ) present inclusion , significant respiratory disease ( moderate severe COPD asthma ) require chronic use corticosteroid ( whatever route administration ) serious digestive malfunction . Patient exist malignancy history malignancy Major psychosocial instability expect lack compliance insulin treatment , psychiatric pathology patient parent , major problem family dynamic ; Signs active infection ; Any patient obesity define BMI ≥ 35 Existence serious malfunction vital organ ; History organ allograft ; Use treatment allow Study ( see Section 8.4.2 ) ; Vaccination alive attenuate virus within 4 week first injection induction period whole maintenance period Pregnant female ( confirmed laboratory test ) lactate Participation another clinical trial previous 3 month ; Lack affiliation social security scheme ( beneficiary assignee ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>IL2</keyword>
	<keyword>Interleukin 2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Auto-immune disease</keyword>
	<keyword>Insulin</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Regulatory T cell</keyword>
	<keyword>Treg</keyword>
	<keyword>Immunoregulation</keyword>
	<keyword>Immune tolerance</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>